ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-0646
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer ; day:1 ; month:1 ; year:2022 ; pages:1-9
Investigational new drugs ; (1.1.2022), 1-9
- Creator
-
Ku, Bo Mi
Heo, Jae Yeong
Kim, Jinchul
sun, Jong-Mu
Lee, Se-Hoon
Ahn, Jin Seok
Park, Keunchil
Ahn, Myung-Ju
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10637-021-01121-6
- URN
-
urn:nbn:de:101:1-2022020921110794105318
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ku, Bo Mi
- Heo, Jae Yeong
- Kim, Jinchul
- sun, Jong-Mu
- Lee, Se-Hoon
- Ahn, Jin Seok
- Park, Keunchil
- Ahn, Myung-Ju
- SpringerLink (Online service)
Other Objects (12)
The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer
An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC
Radiotherapy plus EGFR inhibitors: synergistic modalities
A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer
A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia
Targeting CDK 2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
Machine learning-aided discovery of T790M-mutant EGFR inhibitor CDDO-Me effectively suppresses non-small cell lung cancer growth
QSAR based model for discriminating EGFR inhibitors and non-inhibitors using Random forest
Design, Synthese und Optimierung neuer mutationsspezifischer EGFR Inhibitoren
The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer
An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC
Radiotherapy plus EGFR inhibitors: synergistic modalities
A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer
A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia
Targeting CDK 2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
Machine learning-aided discovery of T790M-mutant EGFR inhibitor CDDO-Me effectively suppresses non-small cell lung cancer growth
QSAR based model for discriminating EGFR inhibitors and non-inhibitors using Random forest
Design, Synthese und Optimierung neuer mutationsspezifischer EGFR Inhibitoren
The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer
An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC
Radiotherapy plus EGFR inhibitors: synergistic modalities
A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer
A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia
Targeting CDK 2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
Machine learning-aided discovery of T790M-mutant EGFR inhibitor CDDO-Me effectively suppresses non-small cell lung cancer growth
QSAR based model for discriminating EGFR inhibitors and non-inhibitors using Random forest